4.1 IAS 38 Intangible Assets — Research & Development

4.1 IAS 38 Intangible Assets — Research & Development

In modern knowledge-driven economies, intangible assets—such as proprietary software, pharmaceutical patents, broadcast licences, customer databases, and brand trademarks—frequently represent the primary source of enterprise value. In the ACCA Financial Reporting (FR) examination, IAS 38 Intangible Assets is a high-frequency testing area across Section A objective test questions, Section B case studies, and Section C financial statement preparation. Candidates must master the strict identifiability criteria, the absolute prohibition against capitalising internally generated brands, the six mandatory PIRATE criteria for capitalising development expenditure, and the subsequent accounting rules for finite versus indefinite useful lives.

---

1. Definition and Core Recognition Criteria

Under IAS 38.8, an intangible asset is formally defined as:

"An identifiable non-monetary asset without physical substance."

To be recognized on the Statement of Financial Position, an expenditure must satisfy three core foundational building blocks: identifiability, control, and future economic benefits, followed by the standard two-tier asset recognition criteria.

                         IAS 38 RECOGNITION ARCHITECTURE
                                        |
        +-------------------------------+-------------------------------+
        |                               |                               |
  IDENTIFIABILITY                    CONTROL                 FUTURE ECONOMIC BENEFITS
  * Separable, OR               * Power to direct use        * Commercial revenues, OR
  * Arises from legal or        * Ability to restrict        * Operational cost savings
    contractual rights            others' access               (e.g., reduced production costs)

The Identifiability Test (IAS 38.12)

An intangible asset meets the identifiability criterion if, and only if, it satisfies at least one of the following two statutory limbs:

1. The Separability Criterion: The asset is capable of being separated or divided from the entity and sold, transferred, licensed, rented, or exchanged, either individually or together with a related contract, identifiable asset, or liability. Examples include transferable patent rights, commercial software licences, and customer contracts that can be sold to a third party.
2. The Contractual or Legal Rights Criterion: The asset arises from contractual or other legal rights, regardless of whether those rights are transferable or separable from the entity or from other rights and obligations. Examples include statutory operating licences (such as airline landing slots or 5G telecommunication spectrum licences), import quotas, and registered trademarks.

If an outlay fails both limbs of the identifiability test, it cannot be recognized as an intangible asset under IAS 38. In a business combination under IFRS 3, non-identifiable expenditures are subsumed within goodwill.

Control and Future Economic Benefits (IAS 38.13–17)

• Control: An entity controls an asset if it possesses the legal power to obtain the future economic benefits flowing from the underlying resource and can restrict the access of competitors to those benefits. Control normally stems from legally enforceable rights (such as patents, copyrights, registered trade secrets, or non-compete agreements).
  • Human Capital and Skilled Staff: Entities often spend heavily training employees. However, because skilled staff can resign and take their skills elsewhere, the entity lacks legal control over the future economic benefits. Staff training costs must always be expensed to profit or loss.
  • Customer Loyalty and Market Share: Customer relationships and brand loyalty cannot be capitalised as standalone assets unless protected by binding legal contracts (such as long-term supply commitments).
• Future Economic Benefits: These benefits may arise as revenues from the sale of goods or services, or as operational cost savings (e.g., a proprietary automated routing algorithm that reduces transport fuel expenses).

General Asset Recognition Criteria (IAS 38.21)

An intangible asset must be recognized if, and only if:

1. It is probable that the expected future economic benefits attributable to the asset will flow to the entity (a probability greater than 50%); and
2. The cost of the asset can be measured reliably.

---

2. Purchased Intangibles vs. Internally Generated Intangibles

IAS 38 establishes distinct regulatory rules depending on whether an intangible asset is acquired externally or developed through internal efforts.

A. Separately Acquired Intangibles (Purchased Intangibles)

When an intangible asset is purchased from an external third party (e.g., purchasing a specialized software licence or acquiring a patented pharmaceutical formula):

• Recognition Presumption: The probability recognition criterion is always deemed to be satisfied because the transaction price reflects market expectations of future economic benefits.
• Cost Measurement: Initial cost comprises the purchase price (including import duties and non-refundable purchase taxes, net of trade discounts) plus any directly attributable costs of preparing the asset for its intended use (such as legal fees and technical testing costs).

B. Acquired in a Business Combination (IFRS 3)

Under IFRS 3 Business Combinations, the acquirer recognizes identifiable intangible assets of the acquiree at their acquisition-date fair value, separately from goodwill. An intangible asset is recognized even if the acquiree had not recognized it prior to the acquisition (e.g., an in-process R&D project or an internally developed trade name), provided it meets the identifiability criterion.

C. Internally Generated Goodwill: Absolute Prohibition

Under IAS 38.48, internally generated goodwill shall not be recognised as an asset.

• Authoritative Rationale: Internally generated goodwill is not an identifiable resource controlled by the entity that can be measured reliably at cost. It reflects the general operating reputation, customer rapport, and enterprise momentum built up over time, which cannot be separated from the business as a whole.
• Only Purchased Goodwill Recognized: Purchased goodwill is recognized strictly in consolidated financial statements upon acquiring a business under IFRS 3, representing the excess of consideration transferred over the fair value of net identifiable assets acquired.

D. Specifically Prohibited Internally Generated Intangibles (IAS 38.63)

To eliminate subjective and speculative balance sheet inflation, IAS 38.63 explicitly prohibits the capitalisation of five specific internally generated items:

  STRICTLY FORBIDDEN FROM CAPITALISATION (IAS 38.63):
  --------------------------------------------------
  1. Internally generated brands
  2. Internally generated mastheads and publishing titles
  3. Internally generated customer lists and subscriber databases
  4. Internally generated customer relationships
  5. Internally generated goodwill

Why the prohibition? Expenditures on internally generated brands, publishing titles, and customer lists cannot be distinguished from the general day-to-day cost of running, advertising, and marketing the business as a whole. All outlays incurred on these items must be expensed immediately to profit or loss as operating expenses.

---

3. Research vs. Development Expenditure & The PIRATE Criteria

For internal technical projects aimed at inventing new products, manufacturing processes, or software applications, IAS 38 divides the project into two chronological stages: the Research Phase and the Development Phase.

Fundamental Rule (IAS 38.53): If an entity cannot distinguish the research phase of an internal project from the development phase, the entire expenditure must be treated as if it were incurred in the research phase only (i.e., expensed in full to profit or loss).

The Six Mandatory Development Capitalisation Criteria: PIRATE

Development expenditure must be capitalised from the exact date on which the entity can demonstrate that all six of the following conditions are simultaneously met:

                      THE SIX PIRATE CAPITALISATION CRITERIA
  ===============================================================================
  [ P ]  Probable future      Demonstrate how the asset will generate probable future
         economic benefits    economic benefits (e.g., existence of a market for output
                              or internal cost savings demonstrated by a feasibility study).
  -------------------------------------------------------------------------------
  [ I ]  Intention            Management possesses a formal, documented commitment
         to complete          and intention to complete the intangible asset and use
                              or sell it.
  -------------------------------------------------------------------------------
  [ R ]  Resources            Availability of adequate technical, financial, and
         available            other resources to complete development and commercialise
                              or deploy the asset.
  -------------------------------------------------------------------------------
  [ A ]  Ability              The entity has the operational ability to use or sell the
         to use or sell       intangible asset upon completion.
  -------------------------------------------------------------------------------
  [ T ]  Technical            The technical feasibility of completing the intangible
         feasibility          asset so that it will be available for use or sale has
                              been established (e.g., functional working prototype).
  -------------------------------------------------------------------------------
  [ E ]  Expenditure          Expenditure attributable to the intangible asset during
         measurable           its development can be reliably measured (e.g., verified
                              engineering timecards, direct materials logs).
  ===============================================================================

Capitalisation Cut-off & Prohibition on Retrospective Reinstatement

• Capitalisation Start Date: Capitalisation commences on the exact calendar day when the last of the six PIRATE criteria is fulfilled.
• No Retrospective Capitalisation (IAS 38.71): Expenditure on an intangible item that was initially recognized as an expense in prior interim or annual reporting periods shall not be recognized as part of the cost of an intangible asset at a later date. Once expensed, costs can never be reinstated.
• Capitalised Costs Include: Direct materials consumed, direct engineering salaries and wages, statutory patent registration fees, and directly attributable testing costs.
• Excluded Costs (Expensed): General corporate administration overheads, selling and marketing launch costs, commercial advertising, and staff training expenses.

---

4. Useful Life: Finite vs. Indefinite & Subsequent Accounting

IAS 38 requires an entity to assess whether the useful life of an intangible asset is finite or indefinite.

                                USEFUL LIFE TAXONOMY
                                         |
        +--------------------------------+--------------------------------+
        |                                                                 |
  FINITE USEFUL LIFE                                            INDEFINITE USEFUL LIFE
  * Foreseeable limit to cash-flow period                       * No foreseeable limit to future net cash inflows
  * Amortised systematically over useful life                   * NEVER amortised (IAS 38.107)
  * Residual value assumed zero (with rare exceptions)          * Mandatory annual impairment testing under IAS 36
  * Tested for impairment only if indicators exist              * Useful life status reviewed annually for change to finite

A. Finite Useful Life Mechanics

• Amortisation Commencement: Begins when the asset is available for use (i.e., in the location and condition necessary for it to operate in the manner intended by management). Amortisation does not wait until commercial production or sales commence.
• Amortisation Cessation: Ceases at the earlier of the date the asset is classified as held for sale under IFRS 5 and the date it is derecognised.
• Amortisation Method: Must reflect the pattern of economic consumption. If that pattern cannot be determined reliably, the straight-line method is mandatory.
• Residual Value: Under IAS 38.100, the residual value of a finite-life intangible is assumed to be zero unless:
  1. A third party has contractually committed to purchase the asset at the end of its useful life; or
  2. There is an active market for the asset, residual value can be determined from that market, and it is probable the market will exist at the end of the asset's life.
• Annual Review: The amortisation period, method, and residual value must be reviewed at least at each financial year-end. Changes are accounted for prospectively as changes in accounting estimates under IAS 8.

B. Indefinite Useful Life & Intangibles Not Yet Available for Use

• Indefinite Life Definition: There is no foreseeable limit to the period over which the asset is expected to generate net cash inflows (e.g., an acquired renewable telecommunications licence).
• Strict Non-Amortisation: Amortisation is strictly prohibited under IAS 38.107.
• Mandatory Annual Impairment Test: Under IAS 36, intangible assets with an indefinite useful life and intangible assets not yet available for use (such as work-in-progress capitalised development) must be tested for impairment annually, irrespective of whether any indicator of impairment exists.

C. Subsequent Expenditure

Under IAS 38.20, subsequent expenditure on an intangible asset after its purchase or completion is almost always recognized as an expense in profit or loss when incurred. In practice, it is virtually impossible to distinguish subsequent expenditure from outlays incurred to maintain or enhance the business as a whole.

---

5. Comprehensive Worked Example: Research, Development & Amortisation

Scenario Details

Novus Pharma Ltd develops a new synthetic drug, "CardioCure", during the financial year ended 31 December 20X4. Project records reveal the following outlays:

1. 1 January 20X4 – 28 February 20X4 (Exploratory Lab Work):
   • Lab consumables consumed in initial molecular screening: $140,000.
   • Salaries of research scientists evaluating compound properties: $110,000.
2. 1 March 20X4 – 31 May 20X4 (Pre-Approval Development Work):
   • Engineering costs constructing a test reactor: $160,000.
   • On 1 March 20X4, technical feasibility was proven and management intended to complete the drug. However, secured long-term bank financing of $1,000,000 required to fund clinical trials was not finalized and legally approved until 1 June 20X4.
3. 1 June 20X4 – 30 September 20X4 (Full Development Stage):
   • From 1 June 20X4, all six PIRATE criteria were simultaneously fulfilled.
   • Specialized clinical trial consumables: $280,000.
   • Salaries of development clinical trial staff: $210,000.
   • Direct statutory safety and regulatory patent filing fees: $70,000.
   • General corporate overheads allocated by head office: $50,000.
4. 1 October 20X4 – 31 December 20X4 (Commercial Readiness & Launch):
   • Development and trial testing were successfully completed on 30 September 20X4. The drug was certified and available for commercial manufacture on 1 October 20X4.
   • Estimated useful economic life is 5 years (60 months) with zero residual value. Straight-line amortisation applies.
   • Staff training costs incurred to instruct sales representatives on drug pharmacology: $45,000.
   • Nationwide medical marketing and advertising campaign incurred in November 20X4: $95,000.

Step 1: Evaluate Expenditure Eligibility

• 1 January to 28 February (Research Phase):
  • Lab consumables ($140,000) and Scientist salaries ($110,000) represent original investigation to gain new scientific knowledge. Expensed immediately to profit or loss = $250,000.
• 1 March to 31 May (Failed PIRATE Criteria):
  • Even though technical feasibility and management intent were present, the "Resources Available" (R) criterion was not satisfied until funding was secured on 1 June. Under IAS 38.57, all 6 criteria must be met simultaneously. Expensed to profit or loss = $160,000.
  • No Retrospective Reinstatement: This $160,000 can never be capitalised at a later date.
• 1 June to 30 September (Eligible Development Phase):
  • All 6 PIRATE criteria were met from 1 June 20X4.
  • Clinical trial consumables: $280,000 (Capitalised)
  • Development clinical trial staff salaries: $210,000 (Capitalised)
  • Regulatory patent filing fees: $70,000 (Capitalised)
  • Allocated group overheads: $50,000 (Expensed to P&L; general overheads cannot be capitalised under IAS 38.67).
  • Total Initial Capitalised Development Cost = $280,000 + $210,000 + $70,000 = $560,000.
• Post-Development Expenditure (1 October to 31 December):
  • Staff training ($45,000): Expensed to P&L (entity cannot control employee knowledge).
  • Advertising and marketing ($95,000): Expensed to P&L (marketing outlays cannot be capitalised).

Step 2: Amortisation for the Year Ended 31 December 20X4

• The asset is available for use on 1 October 20X4. Amortisation runs for 3 months (October, November, December 20X4).
• Useful life = 5 years (60 months); Residual value = $0.

Amortisation Expense = Capitalised Cost * (Months Available / Total Useful Life in Months)
Amortisation Expense = $560,000 * (3 / 60) = $28,000

Carrying Amount at 31 December 20X4 = Initial Cost - Accumulated Amortisation
Carrying Amount at 31 December 20X4 = $560,000 - $28,000 = $532,000

Step 3: Financial Statement Extracts for Year Ended 31 December 20X4

Statement of Profit or Loss Extract:

Operating Expenses:
  Research expenditure ($140,000 + $110,000):         ($250,000)
  Unqualified development costs (March-May):           ($160,000)
  Allocated head office administrative overheads:       ($50,000)
  Staff training expenses:                              ($45,000)
  Marketing and advertising costs:                      ($95,000)
  Amortisation of intangible asset (3 months):          ($28,000)
----------------------------------------------------------------
Total Profit or Loss Charge:                          ($628,000)

Statement of Financial Position Extract as at 31 December 20X4:

Non-Current Assets:
  Intangible Assets (Capitalised Development):
    Gross Capitalised Development Cost:                 $560,000
    Accumulated Amortisation:                            (28,000)
    Carrying Amount:                                    $532,000

---

6. Common Exam Traps & ACCA Examiner Tips

[!WARNING] ACCA Examiner Trap 1: The Retrospective Reinstatement Fallacy The examiner regularly presents scenarios where project costs were expensed in a prior reporting period (or earlier in the current financial year) before PIRATE criteria were fulfilled. When the project subsequently succeeds, candidates often mistakenly capitalise the earlier expensed amounts. IAS 38.71 strictly forbids retrospective reinstatement; costs once expensed can never be capitalised.

[!WARNING] ACCA Examiner Trap 2: The Internally Generated Brand Trap Questions frequently mention an internal valuation of a company's flagship brand name or proprietary customer list. Internally generated brands, publishing titles, and customer lists are strictly prohibited from capitalisation under IAS 38.63. They can only be recognized if purchased separately or acquired in a business combination under IFRS 3.

[!TIP] ACCA Examiner Tip: The Staff Training Boundary Outlays incurred to train staff on newly developed software, specialized systems, or clinical protocols are never capitalised. Because employees can resign and take their skills elsewhere, the entity lacks legal control over the future economic benefits.

[!TIP] ACCA Examiner Tip: Available for Use vs Commercial Launch Amortisation begins on the date the intangible asset is available for use (operational readiness), not when commercial manufacturing commences or when marketing campaigns generate the first dollar of sales revenue.